If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() Journal of Cardiac SurgeryVolume 22 Issue 4, Pages 320 - 322 Published Online: 27 Jul 2007 © 2010 Wiley Periodicals, Inc.
Abstract | References | Full Text: HTML, PDF (Size: 47K) | Related Articles | Citation Tracking Off-Pump Insertion of Continuous Flow Left Ventricular Assist Devices Copyright 2007 by Blackwell Futura Publishing, Inc. (J Card Surg 2007;22:320-322) ABSTRACTAbstract Background and Aim of the Study: Traditional left ventricular assist device (LVAD) implantation requires extensive dissection and use of cardiopulmonary bypass (CPB). Potential adverse effects of CPB in very ill end-stage heart failure patients include right ventricular dysfunction, end-organ injury, and bleeding. We sought to evaluate the feasibility and outcome of LVAD insertion without CPB. Methods: The Jarvik 2000 is an axial-flow pump newly involved in a phase I clinical trial in status I patients as a bridge to transplantation. Seven patients received this pump through thoracotomy or sternotomy with or without the use of CPB. Results: All patients had NYHA class IV heart failure with end-organ dysfunction requiring inotropic therapy. Two were in cardiogenic shock, necessitating full CPB support. Five patients had the Jarvik implanted off-CPB. The off-CPB patients were associated with decreased length of surgery, mechanical ventilation, blood transfusions, inotropic support, and hospital stay including rehabilitation. Nearly all of the patients had complete resolution of liver and kidney dysfunction. Conclusion: We have demonstrated that off-CPB insertion of axial flow LVADs is feasible, safe, and potentially advantageous. Although we are encouraged by the perioperative simplicity of this strategy, we acknowledge that additional implants and comparisons of outcomes with traditional pulsatile and continuous flow device techniques will be necessary to advocate its widespread adoption. |